Emery Pharma: Coronavirus Response

By March 26, 2020

During this historic, unprecedented pandemic crisis, the health and safety of our employees at Emery Pharma and community at large is our top priority. Over the last few weeks, we have transformed the way we work and are actively taking measures to do our part in “flattening the curve”. At the same time, all of us are closely monitoring the COVID-19 situation and taking action per the CDC’s guidances.

https://www.cdc.gov/homepage/images/cdc-in-action/COVID-19-Response-647x381px.jpg(source: CDC.gov)

In the meantime, we remain committed to our mission and supporting our client base, and we want to extend our support to research for prevention, diagnosis, and treatment of COVID-19. As a fully equipped BSL-2 laboratory, our scientists will continue to help clients develop assays, testing kits, and produce data that will help improve outcomes and save lives. Our microbiology, bioanalytical chemistry, and medicinal chemistry labs are well-positioned to support research that will help stop this pandemic.

We want to share some of the actions we are taking:

  • Prevention: Emery Pharma is actively working with partners to help develop and test novel products to eradicate SARS-CoV-2 on surfaces.
  • Diagnosis: Working with our partners to validate and distribute testing kits for COVID-19.
  • Treatment: As a GLP compliant laboratory, we are able to perform PK/PD and bioanalytical testing for repurposing FDA approved drug candidates, as well as support research for any new drug applications (NDA). Our team has extensive experience supporting 505 (b)(1), 505 (b)(2), and 505 (j) applications to the FDA.